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Identification of blood-based molecular signatures for
prediction of response and relapse in schizophrenia
patients
E Schwarz1, PC Guest1, J Steiner2, B Bogerts2 and S Bahn1,3
The current inability of psychiatric medicine to objectively select the most appropriate treatment or to predict imminent relapse
are major factors contributing to the severity and clinical burden of schizophrenia. We have previously used multiplexed
immunoassays to show that schizophrenia patients have a distinctive molecular signature in serum compared with healthy
control subjects. In the present study, we used the same approach to measure biomarkers in a population of 77 schizophrenia
patients who were followed up over 25 months with four aims: (1) to identify molecules associated with symptom severity in
antipsychotic naive and unmedicated patients, (2) to determine biomarker signatures that could predict response over a 6-week
treatment period, (3) to identify molecular panels that could predict the time to relapse in a cross-sectional population of patients
in remission and (4) to investigate how the biological relapse signature changed throughout the treatment course. This led to
identification of molecular signatures that could predict symptom improvement over the first 6 weeks of treatment as well as
predict time to relapse in a subset of 18 patients who experienced recurrence of symptoms. This study provides the groundwork
for the development of novel objective clinical tests that can help psychiatrists in the clinical management of schizophrenia.
Translational Psychiatry (2012) 2, e82; doi:10.1038/tp.2012.3; published online 21 February 2012
Introduction
Less than 50% of schizophrenia patients respond to an
initial treatment with antipsychotic medication.1,2 This is not
surprising as most of the current antipsychotic medications
used in the treatment of schizophrenia were discovered
empirically based on serendipitous clinical observations and
reverse pharmacology.3 Therefore, there is not sufficient
understanding of the underlying pathophysiology of schizo-
phrenia to inform diagnosis. Furthermore, traditional
pharmacotherapy for schizophrenia using ‘blockbuster’
drugs usually leads to the administration and switching of
drugs multiple times until an adequate response is achieved.
It is perhaps not surprising that there is a low treatment
response rate and a high rate of non-compliance often
resulting in relapse.4 Thus, reliable tests with a sound
biological rationale to guide the treatment selection are
needed, as recently suggested in the case of antidepressant
research and development.5
The adoption of new, molecule-based algorithms has not
been common practice in neuropsychiatric research. How-
ever, this is likely to change considering the increased drive
for the improved clinical management and benefit/cost ratios
in schizophrenia treatment, as well as the Food and Drug
Administration’s integrated objective for personalized medi-
cine approaches in managing diseases.6 Cost containment
for clinical trials will also be a sufficient incentive for
pharmaceutical companies to pursue this approach.7
We have previously used multiplexed immunoassays to
show that schizophrenia patients have a distinctive molecular
signature in blood serum.8,9 In this study, we have used the
same method in an attempt to identify molecular serum
signatures that could predict response and subsequent relapse
in 77 schizophrenia patients. The study had four main aims: (1)
to identify molecules associated with symptom severity in
antipsychotic naive and unmedicated patients, (2) to determine
biomarker signatures that could predict response over a 6-
week treatment period, (3) to identify molecular panels that
could predict the time to relapse in a cross-sectional population
of patients in remission and (4) to investigate how the biological
relapse signature changed throughout the treatment course.
For this purpose, 77 initially acutely psychotic schizophrenia
patients were treated for 6 weeks and followed up until relapse
occurred within a 2-year time period.
Methods
Clinical samples. The institutional ethical committee of the
University of Magdeburg approved the protocols of the study,
informed written consent given by all participants and studies
were conducted according to the Declaration of Helsinki. All
diagnoses were carried out using the Diagnostic and
Statistical Manuel (DSM)-IV, and clinical tests were performed
by psychiatrists under good clinical practice-compliance to
minimize variability. Subjects were diagnosed as having the
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paranoid subtype of schizophrenia (295.30). The exclusive
focus on paranoid schizophrenia, which comprises the most
prevalent subtype of the illness, was intended to minimize
variability. Out of 77 patients, 36 were in the first stage of illness
and antipsychotic naı¨ve at the start of the study (Table 1). The
remaining 41 patients had been antipsychotic-free for at least 6
weeks. At T0, the average disease duration was 6.32±8.63
years. All subjects were treated as inpatients over the first 6
weeks of treatment. Clinicians had access to all detailed clinical
files including medical histories by proxy and referral letters from
the general practitioners. Any patients with other medical condi-
tions such as type 2 diabetes, hypertension, cardiovascular
or autoimmune diseases were excluded. Patients with auto-
immune diseases were excluded to rule out psychosis secon-
dary to disorders like systemic lupus erythematodes or multiple
sclerosis, which may cause schizophrenia-like psychotic
symptoms but in the view of the authors rather resemble
organic schizophreniform psychosis than schizophrenia.
During the first 6 weeks of treatment, where all subjects
were treated as inpatients, therapeutic drug monitoring from
peripheral blood samples was applied in order to assess the
compliance.
Blood samples were collected from all subjects by venous
puncture into S-Monovette 7.5ml serum tubes (Sarstedt;
Numbrecht, Germany) at the start of the study (T0), after the
6 week treatment period (T6), at the last clinical visit before
relapse (TR) and during relapse (Figure 1). Serum was
prepared by placing samples at room temperature for 2 h to
allow blood coagulation, followed by centrifugation at 4000 g
for 5min to remove particulate material. The resulting super-
natants were stored at 80 1C in Low Binding Eppendorf
tubes (Hamburg, Germany) before the analysis.
Multiplex immunoassay. The HumanMAP immunoassay
platform was used to measure the serum concentrations of
191 proteins and small molecules (Supplementary Table 1)
in a Clinical Laboratory Improvement Amendments-certified
laboratory at Rules Based Medicine (Austin, TX, USA) as
described previously.9 Samples were randomized and
blinded to analysts using code numbers until all
biochemical assays were complete. Assays were calibrated
using standards, raw intensity measurements converted to
absolute protein concentrations by comparison to the
standards, and performance was verified using quality
control samples. Data analyses were performed using the
statistical software package R (http://www.r-project.org). The
protocol for the study participants, clinical samples and test
methods was carried out in compliance with the Standards
for Reporting of Diagnostic Accuracy (STARD) initiative.10
Data analysis. The molecular data set was preprocessed by
filtering out all analytes, which contained measurements
outside the limits of quantitation in more than 30% of
samples. After this procedure, 168 out of 191 analytes
remained in the data set, and the proportion of missing
values dropped from 16.7 to 6.8%. To assess data quality,
Principal Component Analysis (SIMCA-Pþ vs 12.0,
Umetrics, Umea˚, Sweden) was used for the detection of
strong effects on the overall variance in the filtered data set.
No such effects could be identified across the first 10
principal components, which covered 44% of the variance in
the data set. Shapiro–Wilk analysis showed that the majority
of the investigated analytes (97%) were significantly
(Po0.05) non-normally distributed. Outliers in each analyte
as well as response variables were excluded if a given
concentration differed by more than two standard deviations
from the mean of the respective analyte. For the different
analyses described in the present study, this resulted in the
removal of 3.2–4.1% of subjects per analyte, on average.
Outliers identified in this fashion did not substantially affect
results, as repetition of all analyses without exclusion of
outliers led to qualitatively identical results.
Significant associations were determined using non-para-
metric Spearman’s correlation tests and adjusted for false
Table 1 Demographic details of schizophrenia patients at T0 and at the time of relapse
At T0 At T6 At relapse
n 77 77 18
Sex (m/f) 50/27 50/27 12/6
Age (years) 35.56±11.06 — 40.44±11.89
BMI (kgm2) 25.35±4.61 26.12±4.50 26.23±5.28
Waist circumference (cm) 91.08±14.42 93.55±13.31 92.56±11.92
Hip circumference (cm) 101.20±10.04 103.22±9.29 102.72±8.78
Blood pressure, diastolic (mmHg) 80.65±11.46 76.68±10.80 80.28±9.31
Blood pressure, systolic (mmHg) 129.18±14.91 121.36±14.68 128.89±14.61
Pulse (heart beats per min) 81.81±12.44 77.84±12.41 87.78±15.73
PANSS P1-P7 (score) 22.97±7.17 12.68±5.30 22.11±6.11
PANSS N1-N7 (score) 19.33±8.69 14.36±6.83 17.67±8.24
PANSS G1-G16 (score) 42.99±10.33 28.69±9.09 38.83±13.44
HAMD (score) 17.43±9.59 7.08±6.94 19.33±11.66
Smoking (cigarettes per day) 9.47±9.10 9.57±9.49 10.56±10.09
Cannabis (yes/no) 16/61 3/74 5/13
Medication (olanzapine/quetiapine/risperidone/other) — 18/14/24/21
Cumulative chlorpromazine units (mg) 0 17123±12657
Abbreviations: HAMD, Hamilton D; PANSS, Positive and Negative Syndrome Scale.
Values are shown as mean±s.d.
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discovery rate.11 Comparisons between the two groups were
based on the non-parametric Wilcoxon Rank sum test
or the paired Wilcoxon Rank sum test for within-subject
comparisons. Comparisons between three or more groups
were performed using the non-parametric Kruskal–Wallis
test. Analysis of co-variance (ANCOVA) was used to
account for ‘regression to the mean’ effects between
baseline and follow-up measurements.12 ANCOVA was also
used to estimate the effect of body mass index (BMI) on
molecular differences between the groups. For ANCOVA, all
variables were log10-transformed to approximate normality.
Unadjusted P values of less than 0.05 were considered as
significant.
To identify a molecular fingerprint that could predict patient
responses such as time to relapse, we applied Random
Forests analysis.13 This technique works by building multiple
decision trees and using a majority decision of classification
outputs among trees to assign patients to one of two groups
based on the levels of serum molecules. This method was
also used to select the most important molecules for the
prediction. For this purpose, the measured values of each
molecule were permuted sequentially and the variable
importance was determined from the impact of such
randomization on the classification output.
Results and Discussion
Experimental design. As already mentioned in the
introduction, Multiplex immunoassay analysis was carried
out in four stages (Figure 1):
 The first stage was aimed at the identification of molecules
that correlated with symptom severity in untreated schizo-
phrenia patients. For this purpose, serum was obtained
from 77 patients who were experiencing an episode of
acute psychosis (T0). At this time-point, all patients were
unmedicated or antipsychotic naive. All 77 patients were
followed up over a subsequent 6-week treatment period
with antipsychotic medication.
 The change in symptom severity between T0 and the end of
the 6 week follow-up period (T6) was the main outcome
variable for the second stage of this study. Here, we tried to
identify molecules in the T0 samples that predicted the
change in the symptom severity between T0 and T6.
 For the third stage of the study, we measured serum
molecules at TR, the last clinical visit before patients
relapsed. At this time-point patients were in remission with
different durations of antipsychotic treatment. TR was
chosen since patients at this time-point reflected the real
clinical scenario of a heterogeneous patient population for
which molecular relapse predictors would be most useful.
The aim of this stage was to identify a molecular signature
that could predict the time to relapse for subjects in this
cross-sectional group.
 During the fourth stage, we investigated how the molecular
relapse signature changed throughout the treatment
period.
Patient characteristics and psychopathology scores.
Patient characteristics are indicated in Table 1. As the
symptom severity was the main outcome variable for stages
1–3 of this study, we tested whether this was associated with
any of the remaining recorded patient characteristics. This
was done to identify covariates that could influence the
identification of potential biomarkers. At T0, no significant
associations between PANSS scores and the remaining
patient characteristics were found (Table 2). Secondly, there
were no significant associations between patient
characteristics that were not related to symptom severity
and the change in PANSS between T0 and T6 (DPANSS)
(Table 2).
DPANSS quantifies the symptom improvement that
patients experienced after 6 weeks of antipsychotic treatment.
On average, positive PANSS scores decreased from 23.0 to
12.7 (Po0.001; paired Wilcoxon test) and negative PANSS
scores from 19.3 to 14.4 (Po0.001) (Figure 2). Patients with
more severe symptoms at T0 improved more than those with
less severe symptoms. This is likely to have been influenced
Stage Aim
1 Molecular correlates of 
symptom severity at T0
Blood draw
PANSS assessment
2 T0 molecular predictors of ΔPANSS (T0 vs T6)
3 TR molecular predictors of 
relapse
Change of molecular relapse 
Relapse yes /no
Δ PANSS
4 predictors (T0 to relapse) Changes in relapse signature ?
T0
TIME
T6 TR
77 Patients acutely
psychotic and
unmedicated
77 Patients treated
for six weeks with
antipsychotic
medication
Last visit before
Relapse (0-24 weeks 
after T6). All patients
are in remission
3 weeks – 25 months 
After TR. 18 patients 
are acutely psychotic.
Time to relapse
since last visit
Relapse
Figure 1 Schematic diagram showing time of sampling of schizophrenia patients treated with antipsychotics. Subjects (n¼ 77) were treated for 6 weeks (T0–T6) with
antipsychotics. After this, 0–24 weeks elapsed until the last clinical visit (TR) of the 18 patients who relapsed after an additional 3 weeks to 25 months. Blood samples were
drawn from subjects, serum prepared at the indicated time points and the levels of 190 proteins and small molecules were measured by multiplex immunoassay.
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by ‘regression to themean’, as patients with severe symptoms
are statistically more likely to have a reduction in these
symptoms at the follow-up time-point.14 Therefore, D positive
PANSS was significantly correlated to the T0 PANSS values
(Po0.001, r¼ 0.77; Spearman correlation) (Figure 2). This
was also the case for negative PANSS scores (Po0.001,
r¼ 0.65). As a consequence of the difference in choice of
antipsychotic medication for patients with differing symptom
severity, patients treated with quetiapine improved signifi-
cantly less than those treated with olanzapine or risperidone
(positive PANSS: P¼ 0.001, negative PANSS: P¼ 0.101,
Kruskal–Wallis test). Due to the higher risk of weight gain
associated with olanzapine treatment,15 patients who were
antipsychotic naive at T0 experienced a higher but not
significant increase in BMI until T6 compared to patients
treated with other medications (DBMIOLA¼ 1.1 in olanzapine
group vs DBMIOTHER¼ 0.63 in remaining patients, P¼ 0.200,
Wilcoxon test). This effect was absent in patients who were
not antipsychotic-naive at T0 (DBMIOLA¼ 0.7, DBMIOTHER
¼ 0.8, P¼ 0.845), potentially due to the fact that patients who
had already been treated with olanzapine had also a higher
BMI compared with the remaining patients in this group
(P¼ 0.030, Wilcoxon test). Across all 77 patients, there was
also no significant difference between antipsychotic medica-
tions in the effect on DBMI during the first 6 weeks of
treatment, when patients were treated as inpatients
(P¼ 0.563, Kruskal–Wallis test).
Overall, there was a greater decrease in positive symptoms
(64%) compared with that seen for negative symptoms (40%),
and this was reflected in the number of patients who showed
these responses. For positive symptoms, 52 patients im-
proved by more than 50%. For negative symptoms, only 33
out of the 77 patients showed this improvement. The finding
that T0 positive and negative PANSS scores were not
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Figure 2 Symptom severity measured using PANSS scores during the first 6 weeks of treatment (T0-T6). PANSS positive (top left panel) and negative (bottom left panel)
item scores improved significantly over the treatment period. The lines between T0 and T6 connect scores of the same patients. Right panels: the change in positive (top) and
negative (bottom) PANSS scores were correlated to the corresponding symptom severity at T0.
Table 2 Association between patient characteristics at T0 and symptom
severity
T0 PANSS DPANSS
Data at T0 Positive Negative Positive Negative
Age 0.0747a 0.6270a 0.3552a 0.4529a
Gender 0.2905b 0.7382b 0.7340b 0.3971b
BMI 0.1990a 0.4599a 0.3092a 0.5675a
Waist-circumference 0.2935a 0.4939a 0.4857a 0.8832a
Smoking 0.9021a 0.3390a 0.6040a 0.6175a
Treatment state at T0 0.2785b 0.2809b 0.8660b 0.3960b
The second and third columns show significance (P-values) for the correlations
between patient characteristics and psychopathology (positive and negative
PANSS items) at T0. The fourth and fifth columns show significance (P-values)
for the correlations between patient characteristics at T0 and the change in
PANSS ratings (DPANSS) between T0 and T6.
aSpearman’s correlation test.
bWilcoxon Rank Sum test.
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significantly correlated to each other (P¼ 0.286; Spearman
correlation) suggested that these parameters were indepen-
dent. Likewise,D positive andD negative PANSS scores were
not significantly correlated (P¼ 0.094, r¼ 0.19; Spearman
test).
Stage 1: identification of biomarkers of symptom
severity at T0. During the first stage of the analysis, we
attempted to identify any associations between T0 PANSS
scores and T0 levels of serum molecules. A total of 18
molecules were significantly correlated with positive T0
PANSS scores (14 with r40) and 8 molecules (4 with
r40) were associated with negative T0 PANSS scores
(Po0.05; Spearman correlation; Table 3 shows those
associations with Po0.01). The significant changes
included increased levels of the acute phase response
pathway proteins myoglobin, ferritin, C-reactive protein and
interleukin 16, which have already been implicated in the
pathophysiology of schizophrenia.16 In addition, prolactin
levels showed a significant negative correlation (r¼0.27,
P¼ 0.022) with positive PANSS, indicating that patients with
higher prolactin levels had lower symptom severity at T0.
This is interesting as prolactin has been used as a biomarker
of antipsychotic drug administration for many years,17 and
we have shown recently that levels of this protein are
elevated in serum from first onset antipsychotic naı¨ve
schizophrenia patients.18
Stage 2: identification of biomarkers for response
prediction (DPANSS). In the second stage of this study,
we attempted to identify molecules that could predict the
improvement in PANSS scores between T0 and the end of
the 6 weeks treatment period (T6). For this purpose, we
determined associations between T0 molecular levels and
DPANSS. Due to the ‘regression to the mean’ affecting
DPANSS, we performed ANCOVA analysis using T0 PANSS
levels as covariate.12 This showed that no molecule was
significantly correlated with D positive PANSS and only
insulin showed a weak association with D negative PANSS
(P¼ 0.006, Q¼ 0.47, Table 3). Lower insulin levels at T0
were predictive of symptom improvement after antipsychotic
treatment. This is consistent with previous studies, which
have shown that antipsychotic-induced effects such as
insulin resistance and weight gain are associated with and
may even be required for symptom improvement in response
to antipsychotic treatment.19,20
Stage 3: identification of biomarkers for prediction of
relapse
Univariate predictors of relapse. The next stage of the
analysis was aimed at the identification of a molecular
signature that could predict the time until patients in
remission would relapse. For this purpose, we analyzed the
sera of 18 patients who relapsed after the treatment course
(Table 1). Six patients were off medication at TR and all but
three patients were off medication at the time of relapse. The
time to relapse was quantified as the time between the last
clinical visit (TR) and relapse. These values were
dichotomized such that patients below the median (8.3
months) were partitioned into a short-term relapse group
(n¼ 9) and those above the median were assigned to the
long-term relapse group (n¼ 9). The mean times to relapse
in the short- and long-term relapse groups were 3.7 and 13.2
months, respectively. The classification into short-term and
long-term relapse groups was similar between the scenarios
when time to relapse was determined from either T0 or TR
(16 out of 18 subjects stayed in the same class). This
showed that the assignment of patients to relapse groups
was reasonably consistent throughout the treatment.
To avoid the effect of potential confounding factors on
biomarkers during this stage, we tested the association
between the two relapse groups and all recorded patient
characteristics at TR. Subjects in the short-term relapse group
had significantly lower BMIs compared with those in the long-
term relapse group (24±4 and 28±4 kgm2, respectively;
P¼ 0.040; Wilcoxon test) (Figure 3). This could have been
Table 3 Significant associations between molecular levels at T0 and psychopathology scores
T0 PANSS DPANSS (ANCOVA)
Positive Negative Positive Negative
Molecule P-value q P-value q P-value q P-value q
Fatty acid-binding protein o0.001 0.45
FGF-basic o0.001 0.41 0.003 0.34
Interleukin 16 o0.001 0.40
Creatine kinase MB 0.001 0.40
Myoglobin 0.002 0.36
C-reactive protein 0.003 0.34
NGAL 0.004 0.35
Matrix metalloproteinase 2 0.005 0.33 0.010 0.30
Ferritin 0.008 0.32
Hepatocyte growth factor 0.009 0.31
Osteopontin 0.008 0.32
Amphiregulin 0.009 0.30
Insulin 0.005 0.37
Abbreviations: FGF, fibroblast growth factor-basic; NGAL, neutrophil gelatinase-associated lipocalin.
Columns 2 to 5 show significance (P-value) and correlation coefficients (r) for the association between molecular levels and symptom severity for positive
and negative PANSS scores at T0. Columns 4 to 7 show the corresponding estimates for T0molecular levels with DPANSS (using T0 PANSS levels as covariate).
P-valueso0.01 are shown.
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caused by non-compliance of patients in the short-term
relapse group. The difference in BMIs did not reach
significance at the actual time of relapse (P¼ 0.0625). The
two groups did not differ in age (P¼ 0.232, Wilcoxon test),
gender (P¼ 0.577, Fisher’s exact test), PANSS positive
(P¼ 0.894, Wilcoxon test) or PANNS negative (P¼ 0.824)
scores. We found similar distributions of medication pre-
scribed at T0 (the number of subjects receiving olanzapine/
olanzapineþ risperidone/risperidone/quetiapine/haloperidol/
none was 2/2/2/2/0/1 in the short-term relapse group and 5/0/
1/1/1/1 in the long-term group). There was no significant
difference in time to relapse between olanzapine-treated
patients and those receiving other medications (P¼ 0.348 in
short-term and P¼ 0.111 in long-term relapse group,
P¼ 0.717 in all 18 patients). Also, we did not find an
association of time to relapse with medication status at TR
(P¼ 0.708, Wilcoxon test). This indicated that the six patients
who were off medication at TRwere equally distributed across
the short- and long-term relapse groups. Furthermore, there
was no difference in time to relapse between patients who
were antipsychotic naive or unmedicated at T0 (P¼ 0.328,
Wilcoxon test). This showed that no clinical feature except for
BMI was indicative of the time to relapse at the last clinical
visit. Although time to relapse was not associated with
medication status at the last clinical visit, there is a possibility
that the difference in relapse time was associated with non-
compliance rather than the molecular factors reflecting
response. This is addressed specifically in stage 4.
To identify molecules associated with the time of relapse,
we compared the levels of all molecules at TR with respect to
subjects who ended up in the short- or long-term relapse
groups using non-parametric Wilcoxon tests. This analysis
showed that 27molecules were significantly different between
the groups (Po0.05,Qo0.31). To determine if the significant
difference in BMI values at TR had any effect on the levels of
these molecules, we performed ANCOVA. A total of 13 of
these molecules remained significant (Po0.05) after this
analysis and 11 of the molecules were also significant using
non-parametricWilcoxon tests (Table 4). The threemolecules
with the greatest differences between the short- and long-term
relapse groups were leptin, proinsulin and transforming
growth factor (TGF)-alpha (Figure 3).
The significant association between time to relapse and
BMI, and the finding of higher BMIs in the long-term relapse
group, provided further evidence for the importance of
metabolic changes such as weight gain in antipsychotic
treatment response.21,22 Also, leptin and proinsulin have been
used previously as biomarkers for insulin resistance23 and
metabolic syndrome.24 These findings raise the interesting
possibility that schizophrenia patients who experience little or
no increase in body weight or in the levels of these molecules
in response to antipsychotic treatment are more likely to
relapse. Previous studies have indicated that the levels of
leptin25 and insulin26 are positively correlated with BMI in
patients treated with antipsychotics. However, it is not clear
whether the changes in these two hormones are involved in
the mechanism of action of antipsychotics, if they are due to
side effects or if they are a consequence of changes that occur
in the brain. Previous studies have found that high levels of
insulin can lead to impaired cognition and administration of
insulin-sensitizing agents can reverse this effect.27 Also, it has
been shown that leptin levels are inversely correlated with
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Figure 3 Differences of BMI and the levels of leptin, proinsulin and TGF-a between the short- and long-term relapse groups. The measurements were taken at the last
clinical visit before relapse (TR).
Table 4 Significant molecular differences at the last clinical visit before relapse
(TR) between the short- and long-term relapse groups
Analyte P-value q-value RC
Leptina 0.033 0.559 0.18
Proinsulina 0.021 0.559 0.29
Transforming growth factor alphaa 0.018 0.559 1.85
b-Cellulina 0.015 0.559 0.57
CD5L 0.002 0.335 0.63
Matrix metalloproteinase 9 0.029 0.559 1.40
CD40a 0.011 0.559 0.74
Macrophage-derived chemokine 0.021 0.559 0.74
Brain-derived neurotrophic factor 0.042 0.559 0.77
Apolipoprotein CIa 0.046 0.559 0.78
Matrix metalloproteinase 7 0.045 0.559 0.79
b-2–Microglobulin 0.046 0.559 0.80
Tumor necrosis factor receptor like 2 0.039 0.559 0.85
All molecular differences had a P-value of less than 0.05 after ANCOVA using
BMI at TR as covariate. The q-values represent P-values adjusted for False
Discovery Rate. The RC is the ratio change between the short-term and long
term-relapse groups at TR. Molecules shown in bold were also significant using
non-parametric Wilcoxon tests.
aMolecules selected as important predictors in a multivariate Random Forest
model.
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grey matter volumes in obese subjects, suggesting that high
levels of this hormone can also have negative effects on the
brain function.28
The final objective of stage 3 was an attempt to predict the
time to relapse using serummolecular signatures from the last
clinical visit (TR). The Random Forests technique was used to
select molecules that were the most important determinants
for the prediction of relapse time (short- or long-term) and for
determining the accuracy of this prediction. This led to the
selection of a group of molecules comprised of leptin,
proinsulin, TGF-a, b-cellulin, CD5L, CD40 and Apo CI, which
were also significant in the univariate analysis (see above), as
well as clusterin, insulin, interleukin-8, MIP-1-b and matrix
metalloproteinase 3. Prediction testing using this combination
of molecules yielded an accuracy of 94.5% in determining
whether subjects were in the short- or long-term relapse
groups.
We also tested the BMI values at the last clinical visit (TR)
as a potential predictor of relapse time. Interestingly, another
round of Random Forest analysis did not result in selection
of BMI as an important variable, although 11 out of the 12
molecules indicated above were reselected (excluding matrix
metalloproteinase 3). BMI alone achieved a predictive
performance of 83.4%, which was lower than that achieved
using the signature of 12 molecules indicated above.
Stage 4: changes in the relapse biomarker signature
induced by treatment. In the final stage of this study, we
performed an exploratory analysis into the change in
molecular predictors of relapse throughout the treatment
period. For 15 of the 18 patients who experienced relapse,
samples were available at T0 and T6. Similar to the findings
at TR, patients in the short-term relapse group (n¼ 7) had a
lower BMI at T0 compared to those in the long-term relapse
group (n¼ 8), although this difference was not significant
(P¼ 0.094; Wilcoxon test). At T0, 8 molecules showed
significantly different levels between the short- and long-
term relapse groups (Po0.05, Wilcoxon test), including
leptin (P¼ 0.040), although (Supplementary Table 1) all of
these molecules had a high false discovery rate. This
demonstrated that at T0 there were no pronounced
molecular differences between the two relapse groups.
Therefore, we tested the multivariate biomarker signature
identified above to determine if this was altered at T0. A
Random Forests algorithm comprising these molecules was
tested using T0 samples from the same patients. All patients
who were detected in the short-term relapse group at TR were
also identified at T0. Interestingly, the molecular signature at
T0 also predicted imminent relapse for 50% of the patients (4
out of 8) in the long-term relapse group. Although based on a
low n-number, this may suggest that the molecular state at T0
was more predictive of relapse than when measured at TR.
This could indicate that at T0, when patients were unmedi-
cated and acutely psychotic, their molecular profile was
suggestive of imminent relapse. During the treatment the
molecular profile might have responded in those patients, who
would only relapse after a longer period of time.
With this in mind, we analyzed whether serum molecules of
subjects in short- and long-term treatment groups showed
differences in early response to medication. For this purpose,
the change in serum levels of molecules between T0 and T6
was compared between the two relapse groups. ANCOVA
analysis was performed using baseline molecular levels as
covariates to prevent a potential ‘regression to the mean’ on
results.12 We found that eight molecules were associated with
the time of relapse (Po0.05). For example, the early
treatment response of leptin, insulin and C-peptide were
significantly different between the relapse groups (Po0.041;
Q¼ 0.52, Figure 4). Levels of these three molecules showed
essentially no change in the group that relapsed early,
although these were increased significantly in patients who
relapsed later. Other molecules that showed a differential
early treatment response between the relapse groups are
listed in Supplementary Table 2. In addition, the short-term
relapse group had a lower BMI increase (DBMI¼ 0.28 kgm2)
between T0 and T6 compared with the patients who relapsed
later (DBMI¼ 1.94 kgm2). These findings support the
hypothesis stated above that early response to medication,
which affects metabolic and other processes, are related to
predisposition for subsequent relapse. The result is of
particular importance for the present study, as patients were
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Figure 4 Differential early response to treatment (between T0 and T6) of leptin, insulin and C-peptide between the short- and long-term relapse groups. The figure shows
the difference in the change of levels between T0 and T6 in serum from patients in the two different relapse groups.
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inpatients between T0 and T6 and non-compliance could be
ruled out by therapeutic drug monitoring. The differential early
molecular response to medication may open up the possibility
for the development of molecular tests that allow assessment
of states indicative of relapse and identify those subjects who
may require a change in treatment strategy.
As a final step of stage 4, we investigated the molecular
state in samples taken from subjects at the time of relapse.
This revealed that 12 serum molecules had significantly
different concentrations between the two relapse groups
(Table 5). Again, abnormalities were pronounced for leptin,
insulin, proinsulin and C-peptide, consistent with differences
in BMI between the relapse groups and the suggestion of
altered insulin signalling as seen by an increased insulin/
glucose ratio.
Conclusion
Non-compliance is a serious issue in the treatment of
psychiatric conditions, such as schizophrenia given that this
is the most common cause leading to psychotic relapse. This
is the first study to identify serum molecules that may be
indicative of relapse. Further development of assays targeting
these specific molecules could lead to the development of
useful tests to guide the clinical management of schizophre-
nia. As these molecular signatures may be dynamic and
change over the course of treatment, we also investigated the
change in molecular levels at the initiation of treatment up to
and including the time of relapse. The results suggested that
molecular processes associated with weight gain and
metabolism changes have a central role in re-occurrence of
psychotic symptoms. Specifically, a lower BMI and non-
response of the molecular signature to treatment was
associated with a shorter time to relapse. The identification
of biomarkers, such as the insulin-related molecules proinsu-
lin, C-peptide and insulin, along with changes in the hormone
leptin, is consistent with previous studies showing changes in
these molecules in first onset antipsychotic naive schizo-
phrenia patients.18,29,30 We have also identified molecular
signatures associated with symptom severity and response.
However, the prediction of positive symptom improvement
was of limited value due to the high proportion of patients in this
study who showed an improvement in response to treatment.
Our results extend our previous findings that schizophrenia
is characterized by a reproducible, peripheral signature.
Further testing of these findings in validation studies using
larger numbers of subjects in prospective clinical trials are
required for the development of molecular tools, which could
be useful in guiding the clinical management of schizophrenia.
This could be particularly important for early monitoring of
response to ensure a better clinical outcome in schizophrenia
patients treated with antipsychotics. It may also provide an
early indication for cases in which switching of antipsychotics
may be required.
Limitations. The findings need to be validated in analyses
of further, independent cohorts, in particular in the light of the
regression towards the mean effect observed in this follow-up
study. Also, the prediction of positive symptom improvement
may be of limited value due to the high proportion of patients
who improved after treatment. It will be important to validate
these findings using a cohort of responsive and non-response
patients. Finally, it is not clear whether any of the changes in
biomarker profiles are involved in the mechanism of action of
antipsychotics or if they are a consequence of changes that
occur in the brain. Studies, which have found that hyper-
insulinemia can affect cognition, provide some evidence that
the response of some molecules could be mechanism based.
However, further studies will be required to answer this question.
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